HSV-1 VP16 Inhibitors
HSV-1 VP16 inhibitors are a class of chemical compounds that specifically target and inhibit the activity of **VP16**, a viral protein encoded by Herpes Simplex Virus type 1 (HSV-1). VP16, also known as α-trans-inducing factor (α-TIF), plays a critical role in initiating the transcription of viral immediate early (IE) genes, which are essential for the early stages of the viral replication cycle. VP16 interacts with host cellular factors, including the host transcription machinery, to drive the expression of these IE genes. By inhibiting VP16, these compounds block this interaction and thus disrupt the activation of the viral gene expression program. This inhibition offers valuable insights into the early molecular events of HSV-1 infection and helps elucidate the mechanisms by which VP16 orchestrates the virus's ability to hijack host cellular processes for its own replication.
The study of HSV-1 VP16 inhibitors allows researchers to dissect the complex interplay between viral and host proteins during the early stages of infection. Inhibiting VP16 provides a tool for understanding how the suppression of immediate early gene expression impacts the overall replication cycle of HSV-1 and how the virus establishes its life cycle within host cells. Furthermore, VP16 inhibitors can be used to explore broader questions about viral-host interactions, such as how viral proteins modify host transcriptional machinery to suit viral needs. These inhibitors are valuable for studying the fundamental processes of viral transcription, viral replication strategies, and the dynamic host-pathogen relationship, ultimately deepening our understanding of the molecular biology of HSV-1.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Acyclovir | 59277-89-3 | sc-202906 sc-202906A | 50 mg 500 mg | $150.00 $940.00 | 2 | |
By mimicking guanosine nucleoside, acyclovir can be incorporated into viral DNA, leading to premature DNA chain termination, which in turn could downregulate HSV-1 VP16 by curtailing viral genome replication. | ||||||
Valaciclovir | 124832-26-4 | sc-507443 | 100 mg | $1300.00 | ||
Valacyclovir, once metabolized into acyclovir, can inhibit the viral DNA polymerase enzyme, thereby decreasing the replication of HSV-1 and consequentially reducing the expression levels of VP16. | ||||||
Ganciclovir | 82410-32-0 | sc-203963 sc-203963A | 50 mg 250 mg | $233.00 $421.00 | 1 | |
Ganciclovir acts as a substrate for viral DNA polymerase, leading to DNA chain elongation inhibition, which could decrease the synthesis of viral components necessary for VP16 expression. | ||||||
Cidofovir | 113852-37-2 | sc-482141 | 50 mg | $135.00 | ||
Cidofovir, after conversion to its diphosphate form, competitively inhibits viral DNA polymerase, which could lead to a reduction in VP16 expression by hindering viral DNA synthesis. | ||||||
Trifluorothymidine | 70-00-8 | sc-222370 sc-222370A | 100 mg 1 g | $179.00 $500.00 | 1 | |
Trifluorothymidine (Trifluridine) is incorporated into viral DNA, causing mutations and thymidine kinase inhibition, which could disrupt HSV-1 replication and thus inhibit VP16 protein synthesis. | ||||||
Ribavirin | 36791-04-5 | sc-203238 sc-203238A sc-203238B | 10 mg 100 mg 5 g | $63.00 $110.00 $214.00 | 1 | |
Ribavirin can induce lethal mutagenesis in RNA viruses and inhibit inosine monophosphate dehydrogenase, potentially leading to a reduction in nucleotide pools necessary for HSV-1 and VP16 expression. | ||||||
Phosphonoacetic acid | 4408-78-0 | sc-215712 sc-215712A | 10 g 50 g | $82.00 $327.00 | ||
Phosphonoacetic acid selectively targets viral DNA polymerase, which could lead to an inhibition of viral DNA replication and a subsequent decrease in VP16 expression. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $83.00 | 5 | |
Leflunomide inhibits dihydroorotate dehydrogenase, an enzyme involved in pyrimidine synthesis, potentially leading to a depletion of the pyrimidine pool required for HSV-1 replication and VP16 protein production. | ||||||
Tenofovir | 147127-20-6 | sc-204335 sc-204335A | 10 mg 50 mg | $157.00 $646.00 | 11 | |
Tenofovir disrupts reverse transcriptase activity in retroviruses and might reduce HSV-1 VP16 expression by inhibiting the viral RNA-dependent DNA polymerase when HSV-1 reverse transcribes its mRNA. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate inhibits dihydrofolate reductase, leading to a reduction in thymidine and, consequently, DNA synthesis, which could indirectly result in lower levels of VP16 by inhibiting overall viral replication. | ||||||